Date of submission of the HTAC Recommendation: 12 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), Gefitinib (250 mg tablet and film-coated tablet), and Afatinib continue reading : HTA COUNCIL FINAL RECOMMENDATION ON ERLOTINIB (25 mg, 100 mg, and 150 mg FILM-COATED TABLET), GEFITINIB (250 mg TABLET and FILM-COATED TABLET), AND AFATINIB (20 mg, 30 mg, and 40 mg FILM-COATED TABLET) FOR THE TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) (WITH SECRETARY OF HEALTH DECISION)
HTA COUNCIL FINAL RECOMMENDATION ON ATEZOLIZUMAB [60 mg/mL, 20 mL VIAL FOR INTRAVENOUS (IV) INFUSION] + BEVACIZUMAB [25 mg/mL, 4 mL or 16 mL VIAL FOR IV INFUSION] AND LENVATINIB [4 mg or 10 mg CAPSULE] FOR ADULTS DIAGNOSED WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (uHCC) (WITH SECRETARY OF HEALTH DECISION)
Date of submission of the HTAC Recommendation: 19 January 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on (1) Atezolizumab [60 mg/mL, 20 mL vial for intravenous (IV) infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 continue reading : HTA COUNCIL FINAL RECOMMENDATION ON ATEZOLIZUMAB [60 mg/mL, 20 mL VIAL FOR INTRAVENOUS (IV) INFUSION] + BEVACIZUMAB [25 mg/mL, 4 mL or 16 mL VIAL FOR IV INFUSION] AND LENVATINIB [4 mg or 10 mg CAPSULE] FOR ADULTS DIAGNOSED WITH ADVANCED OR UNRESECTABLE HEPATOCELLULAR CARCINOMA (uHCC) (WITH SECRETARY OF HEALTH DECISION)
HTA COUNCIL FINAL RECOMMENDATION ON MENINGOCOCCAL POLYSACCHARIDE GROUPS A, C, W-135 AND Y CONJUGATE VACCINE FOR ACTIVE IMMUNIZATION OF INDIVIDUALS FROM THE AGE OF 6 WEEKS AGAINST INVASIVE MENINGOCOCCAL DISEASES CAUSED BY NEISSERIA MENINGITIDIS GROUP A, C, W-135 AND Y (WITH SECRETARY OF HEALTH DECISION)
Date of submission of the HTAC Recommendation: 10 February 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health concurs with final recommendation of the HTA Council on Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for active immunization of individuals from the age of 6 weeks; continue reading : HTA COUNCIL FINAL RECOMMENDATION ON MENINGOCOCCAL POLYSACCHARIDE GROUPS A, C, W-135 AND Y CONJUGATE VACCINE FOR ACTIVE IMMUNIZATION OF INDIVIDUALS FROM THE AGE OF 6 WEEKS AGAINST INVASIVE MENINGOCOCCAL DISEASES CAUSED BY NEISSERIA MENINGITIDIS GROUP A, C, W-135 AND Y (WITH SECRETARY OF HEALTH DECISION)
HTA COUNCIL FINAL RECOMMENDATION ON THERMAL ABLATION FOR THE TREATMENT OF PREMALIGNANT LESIONS OF THE CERVIX AMONG WOMEN 30 TO 65 YEARS OLD WHO ARE DEEMED ELIGIBLE FOR ABLATION IN ACCORDANCE TO THE WORLD HEALTH ORGANIZATION (WHO) SCREEN-TREAT APPROACH OR SCREEN-TRIAGE-TREAT APPROACH (WITH SECRETARY OF HEALTH DECISION)
Date of submission of the HTAC Recommendation: 04 December 2025Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Thermal Ablation for the treatment of premalignant lesions of the cervix among women 30 to 65 years old who continue reading : HTA COUNCIL FINAL RECOMMENDATION ON THERMAL ABLATION FOR THE TREATMENT OF PREMALIGNANT LESIONS OF THE CERVIX AMONG WOMEN 30 TO 65 YEARS OLD WHO ARE DEEMED ELIGIBLE FOR ABLATION IN ACCORDANCE TO THE WORLD HEALTH ORGANIZATION (WHO) SCREEN-TREAT APPROACH OR SCREEN-TRIAGE-TREAT APPROACH (WITH SECRETARY OF HEALTH DECISION)
HTA COUNCIL FINAL RECOMMENDATION ON AFLIBERCEPT [40mg/mL SOLUTION FOR INTRAVITREAL INJECTION], RANIBIZUMAB [10 mg/mL SOLUTION FOR INTRAVITREAL INJECTION], AND DEXAMETHASONE IMPLANT [700 mcg INTRAVITREAL IMPLANT] FOR THE TREATMENT OF RETINAL DISEASES (WITH SECRETARY OF HEALTH DECISION)
Date of submission of the HTAC Recommendation: 27 January 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on the following drugs for their respective indications through the Department of Health (DOH) Department Circular No. 2026-0216 “Inclusion of continue reading : HTA COUNCIL FINAL RECOMMENDATION ON AFLIBERCEPT [40mg/mL SOLUTION FOR INTRAVITREAL INJECTION], RANIBIZUMAB [10 mg/mL SOLUTION FOR INTRAVITREAL INJECTION], AND DEXAMETHASONE IMPLANT [700 mcg INTRAVITREAL IMPLANT] FOR THE TREATMENT OF RETINAL DISEASES (WITH SECRETARY OF HEALTH DECISION)